المؤلفون: Figg, William D., Hussain, Maha H., Gulley, James L., Arlen, Philip M., Aragon-Ching, Jeanny B., Petrylak, Daniel P., Higano, Celestia S., Steinberg, Seth M., Chatta, Gurkamal S., Parnes, Howard, Wright, John J., Sartor, Oliver, Dahut, William L.

المصدر: Journal of Urology; Mar2009, Vol. 181 Issue 3, p1104-1113, 10p

مصطلحات موضوعية: PROSTATE cancer treatment, PLACEBOS, THALIDOMIDE, ANDROGENS, PROSTATE-specific antigen, DRUG administration, CANCER in men

مصطلحات جغرافية: UNITED States

الشركة/الكيان: NATIONAL Cancer Institute (U.S.)

المؤلفون: Gong J; Cedars-Sinai Medical Center, Los Angeles, CA., Mita AC; Cedars-Sinai Medical Center, Los Angeles, CA., Wei Z; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Cheng HH; University of Washington, Seattle, WA., Mitchell EP; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA., Wright JJ; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Ivy SP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Wang V; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Gray RC; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Bethesda, MD., Hamilton SR; City of Hope Comprehensive Cancer Center, Duarte, CA., Alva AS; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center, Boston, MA.

المصدر: JCO precision oncology [JCO Precis Oncol] 2024 Apr; Vol. 8, pp. e2300406.

نوع المنشور: Clinical Trial, Phase II; Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/drug therapy , Neoplasms*/genetics , Pyrazoles*/therapeutic use , Quinoxalines*, Humans ; Middle Aged ; United States ; Urinary Bladder Neoplasms ; Receptors, Fibroblast Growth Factor/genetics

المؤلفون: Johnson DB; Vanderbilt University Medical Center, Nashville, Tennessee. douglas.b.johnson@vumc.org., Zhao F; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., Noel M; University of Rochester, Rochester, New York., Riely GJ; Memorial Sloan Kettering Cancer Center, New York, New York., Mitchell EP; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania., Wright JJ; National Cancer Institute, Bethesda, Maryland., Chen HX; National Cancer Institute, Bethesda, Maryland., Gray RJ; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., Li S; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, Massachusetts., McShane LM; National Cancer Institute, Bethesda, Maryland., Rubinstein LV; National Cancer Institute, Bethesda, Maryland., Patton D; National Cancer Institute, Bethesda, Maryland., Williams PM; Frederick National Laboratory for Cancer Research, Bethesda, Maryland., Hamilton SR; University of Texas MD Anderson Cancer Center, Houston, Texas., Conley BA; National Cancer Institute, Bethesda, Maryland., Arteaga CL; UT Southwestern Simmons Cancer Center, Dallas, Texas., Harris LN; National Cancer Institute, Bethesda, Maryland., O'Dwyer PJ; University of Pennsylvania, Philadelphia, Pennsylvania., Chen AP; National Cancer Institute, Bethesda, Maryland., Flaherty KT; Massachusetts General Hospital, Boston, Massachusetts.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Apr 15; Vol. 26 (8), pp. 1812-1819. Date of Electronic Publication: 2020 Jan 10.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Mutation* , Oncogene Proteins, Fusion*, Lymphoma/*drug therapy , Neoplasms/*drug therapy , Protein Kinase Inhibitors/*therapeutic use , Proto-Oncogene Proteins B-raf/*genetics , Pyridones/*therapeutic use , Pyrimidinones/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Lymphoma/genetics ; Lymphoma/pathology ; Male ; Middle Aged ; National Cancer Institute (U.S.) ; Neoplasms/genetics ; Neoplasms/pathology ; Survival Rate ; Treatment Outcome ; United States

المؤلفون: Lam ET; Departments of Internal Medicine, Center for Biostatistics, The Ohio State University, Columbus, OH, USA. manisha.shah@osumc.edu, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2010 May 10; Vol. 28 (14), pp. 2323-30. Date of Electronic Publication: 2010 Apr 05.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Benzenesulfonates/*therapeutic use , Carcinoma, Medullary/*drug therapy , Protein Kinase Inhibitors/*therapeutic use , Pyridines/*therapeutic use , Thyroid Neoplasms/*drug therapy, Administration, Oral ; Adult ; Aged ; Benzenesulfonates/administration & dosage ; Benzenesulfonates/adverse effects ; Biomarkers, Tumor/metabolism ; Carcinoma, Medullary/enzymology ; Carcinoma, Medullary/genetics ; Carcinoma, Medullary/mortality ; Carcinoma, Medullary/secondary ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Mutation ; Niacinamide/analogs & derivatives ; Phenylurea Compounds ; Positron-Emission Tomography ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Proto-Oncogene Mas ; Proto-Oncogene Proteins c-ret/antagonists & inhibitors ; Proto-Oncogene Proteins c-ret/genetics ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Sorafenib ; Thyroid Neoplasms/enzymology ; Thyroid Neoplasms/genetics ; Thyroid Neoplasms/mortality ; Thyroid Neoplasms/pathology ; Time Factors ; Tomography, X-Ray Computed ; Treatment Outcome ; United States ; Young Adult

المؤلفون: Wright JJ; National Cancer Institute, Bethesda, MD, USA., Zerivitz K, Schoenfeldt M

المصدر: Oncology (Williston Park, N.Y.) [Oncology (Williston Park)] 2003 May; Vol. 17 (5), pp. 677-80, 683-6, 691-2.

نوع المنشور: Directory

بيانات الدورية: Publisher: MultiMedia Healthcare Country of Publication: United States NLM ID: 8712059 Publication Model: Print Cited Medium: Print ISSN: 0890-9091 (Print) Linking ISSN: 08909091 NLM ISO Abbreviation: Oncology (Williston Park) Subsets: MEDLINE

مواضيع طبية MeSH: Clinical Trials as Topic*, Antineoplastic Agents/*therapeutic use , Neoplasms/*drug therapy , Protease Inhibitors/*therapeutic use, Boronic Acids ; Bortezomib ; Hematologic Neoplasms/drug therapy ; Hematologic Neoplasms/pathology ; Humans ; National Institutes of Health (U.S.) ; Neoplasms/pathology ; Patient Selection ; Pyrazines ; United States